EHA 2025 | The unmet needs and challenging subgroups in pediatric ALL
In this video, Erica Brivio, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, briefly comments on the unmet needs in pediatric acute lymphoblastic leukemia (ALL), namely the difficulties in treating patients who remain measurable residual disease (MRD) positive or experience relapse soon after treatment with targeted therapies, such as inotuzumab ozogamicin. She also highlights the need to move effective therapies to the frontline setting, thereby reducing the number of relapses occurring in this patient population. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a very broad question. If I start from our patient population, so the relapsed children, and in particular this cohort that we have studied in our ITCC-059 Stratum3 cohort, there are still patients with high risk genetic characteristics that, although may respond with inotuzumab remain MRD positive, and then also patients that relapsed quite quickly or that relapsed anyway after inotuzumab...
This is a very broad question. If I start from our patient population, so the relapsed children, and in particular this cohort that we have studied in our ITCC-059 Stratum3 cohort, there are still patients with high risk genetic characteristics that, although may respond with inotuzumab remain MRD positive, and then also patients that relapsed quite quickly or that relapsed anyway after inotuzumab. So treating these patients is becoming very challenging. So we still need to find the best way to treat them in a curative way. And in general, I think we have found a lot of promising results with immunotherapy like targeted treatment like inotuzumab but also blinatumomab as it is known. Now the major challenge in pediatric ALL is to move all these drugs in frontline treatment so then we don’t need to treat any more relapsed children we just have a very good treatment in frontline with less toxicity so that’s our challenge for the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Institutional funding: Pfizer.
